German pharmaceutical company Bayer recently announced positive results from two Phase III trials of its new menopausal relief drug, elinzanetant. The drug aims to reduce vasomotor symptoms, particularly hot flashes, which are common during menopause. The announcement is significant for Bayer’s pharmaceutical division following a series of challenges in drug development. The clinical trials demonstrated that elinzanetant significantly reduces the frequency and…
Dr. Reddy’s Laboratories, a global pharmaceutical company headquartered in India, has acquired MenoLabs, a women’s health and dietary supplement brand, as part of Amyris Chapter 11 sales process. This acquisition was conducted through an auction, with Dr. Reddy’s successfully bidding $3 million for the women’s supplements label according to court documents. MenoLabs’ portfolio, now a part of Dr. Reddy’s offerings, includes seven…
Astellas Pharma has announced the approval of VEOZA (fezolinetant) by the European Commission for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. Vasomotor symptoms, which include hot flashes and night sweats, are common during menopause. Studies indicate that more than half of women between the ages of 40 and 64 in Europe experience VMS, with some areas reporting…
OOVA, a women’s health platform specializing in remote hormone monitoring, has unveiled its new at-home Perimenopause Hormone Kit. The kit, unique in its approach according to the company, features urine-based multi-hormone biomarkers, including estrogen (E3G), and is complemented by an app that offers real-time data tracking. Differing from traditional blood or FSH-only urine tests, the OOVA kit enables a comprehensive 15-day hormone…
Healthtech company Bone Health Technologies has recently been awarded its fourth patent, marking a significant milestone in the journey of its product, Osteoboost. The wearable device is at the forefront of addressing osteopenia and osteoporosis in post-menopausal women, two conditions that significantly impact bone health. Osteoboost’s design and innovative approach have made it the first device of its kind to demonstrate a…
Pharmavite, known for its Nature Made vitamins, has expanded its presence in the women’s health market with the acquisition of Bonafide Health for $425 million. This move adds Bonafide Health, alongside Uqora and Equelle, to Pharmavite’s portfolio, reinforcing its status as a frontrunner in providing innovative and science-backed health solutions for women. Founded in 2017, Bonafide Health has been working on creating…
The National Menopause Foundation has announced the launch of the Women’s Midlife Health Policy Institute (WMHPI), an initiative aimed at improving research, education, and policy development focused on women’s health during midlife, specifically addressing the challenges of menopause. In the United States, about 1.3 million women enter menopause each year, and by 2025, the number of postmenopausal women worldwide is expected to…
Berlin-based femtech startup Frieda Health has secured EUR 2.5 million in pre-seed funding from the Maximon Longevity Co-Investment Fund, an investor and company builder specializing in the longevity sector. This investment will support Frieda Health’s ongoing development of a digital health platform focused on women’s health, particularly for those aged 45 and above, during menopause. The platform developed by Frieda Health integrates…
